Rutger H T Koornstra
Overview
Explore the profile of Rutger H T Koornstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bol K, Schreibelt G, Bloemendal M, van Willigen W, Hins-de Bree S, de Goede A, et al.
Nat Commun
. 2024 Feb;
15(1):1632.
PMID: 38395969
Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C...
2.
Bloemendal M, Bol K, Boudewijns S, Gorris M, de Wilt J, Croockewit S, et al.
Oncoimmunology
. 2022 Dec;
11(1):2015113.
PMID: 36524210
We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). Fifteen patients with completely resected...
3.
van Wilpe S, Simnica D, Slootbeek P, van Ee T, Pamidimarri Naga S, Gorris M, et al.
Oncoimmunology
. 2022 Jul;
11(1):2094133.
PMID: 35800157
Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs)....
4.
van Wilpe S, Sultan S, Gorris M, Somford D, Kusters-Vandevelde H, Koornstra R, et al.
Cancer Immunol Immunother
. 2022 Jun;
72(1):137-149.
PMID: 35771253
Background: Whereas neoadjuvant cisplatin-based chemotherapy (NAC) followed by a radical cystectomy remains the standard treatment for patients with muscle-invasive bladder cancer (MIBC), increasing evidence suggests that checkpoint inhibitors, either alone...
5.
van Wilpe S, Gorris M, van der Woude L, Sultan S, Koornstra R, van der Heijden A, et al.
Front Immunol
. 2022 Jan;
12:802877.
PMID: 35046958
Checkpoint inhibitors targeting PD-(L)1 induce objective responses in 20% of patients with metastatic urothelial cancer (UC). CD8 T cell infiltration has been proposed as a putative biomarker for response to...
6.
van Wilpe S, Wosika V, Ciarloni L, Hosseinian Ehrensberger S, Jeitziner R, Angelino P, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572887
Although immune checkpoint inhibitors improve median overall survival in patients with metastatic urothelial cancer (mUC), only a minority of patients benefit from it. Early blood-based response biomarkers may provide a...
7.
Tolmeijer S, Koornstra R, de Groot J, Geerlings M, van Rens D, Boers-Sonderen M, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359813
For patients with newly diagnosed metastatic melanoma, rapid BRAF mutation (mBRAF) assessment is vital to promptly initiate systemic therapy. Additionally, blood-based biomarkers are desired to monitor and predict treatment response....
8.
van Wilpe S, Tolmeijer S, Koornstra R, de Vries I, Gerritsen W, Ligtenberg M, et al.
Cancers (Basel)
. 2021 Jun;
13(9).
PMID: 34067105
Homologous recombination repair deficiency (HRD) can be observed in virtually all cancer types. Although HRD sensitizes tumors to DNA-damaging chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, all patients ultimately develop resistance...
9.
van Willigen W, Bloemendal M, Boers-Sonderen M, de Groot J, Koornstra R, van der Veldt A, et al.
Oncoimmunology
. 2021 Jan;
9(1):1738814.
PMID: 33457087
Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III) melanoma. Based on...
10.
Boudewijns S, Bloemendal M, De Haas N, Westdorp H, Bol K, Schreibelt G, et al.
Cancer Immunol Immunother
. 2020 Jan;
69(3):477-488.
PMID: 31980913
Background: Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance...